This study demonstrates that a slow metabolism‐driven amplification of hepatic PPARγ agonism mediates BBR‐induced obesity‐specific hepatic steatosis and subsequent DILI, which also emphasizes the importance of the reduced hepatic drug metabolism capacity in patients with obesity or pre‐existing NAFLD in both clinical practice and drug discovery processes. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.